Pazopanib is an antineoplastic agent utilized for treating advanced renal cell cancer and advanced soft tissue sarcoma in patients who have undergone prior chemotherapy. This small molecule functions as an inhibitor of multiple protein tyrosine kinases, demonstrating potential antineoplastic activity. By targeting vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-alpha, PDGFR-beta), and c-kit, which are integral to the angiogenesis pathway, pazopanib hinders tumor blood vessel formation, ultimately impeding tumor survival and growth. Notably, it achieves steady-state concentrations conducive to maximal inhibition of VEGFR2 phosphorylation and exhibits anti-tumor effects, leading to a reduction in tumor blood flow, increased tumor apoptosis, inhibited growth, and hypoxia in cancer cells. Although absorption is slow and incomplete, with nonlinear tendencies over a dose range of 50-2000 mg, pazopanib's potency in targeting key receptors underscores its significance as a therapeutic option for patients with advanced renal cell cancer and advanced soft tissue sarcoma.

Pazopanib Pathway References